Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET) (Q28165540)
Jump to navigation
Jump to search
scientific article (publication date: October 2003)
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET) |
scientific article (publication date: October 2003) |
Statements
Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET) (English)
0 references
1 October 2003
0 references
42
0 references
7
0 references
1188-95
0 references